What is the recommended acute treatment and subsequent urate‑lowering management for a patient presenting with a gout flare?

Management of Gout: Acute Treatment and Urate-Lowering Therapy

Acute Gout Flare Treatment

For an acute gout flare, initiate treatment within 24 hours using NSAIDs, oral corticosteroids, or colchicine as first-line options, with the choice based on patient comorbidities rather than agent superiority—all three are equally effective when started early. 1, 2, 3

First-Line Treatment Selection Algorithm

The single most critical factor for success is early initiation within 12-24 hours, not which specific agent you choose. 1, 2, 3 Here's how to select:

Choose Oral Corticosteroids (Prednisone 30-35 mg daily for 5 days) if patient has: 1, 2, 3

• Renal impairment (CKD stage ≥3 or eGFR <30 mL/min)
• Cardiovascular disease or uncontrolled hypertension
• History of peptic ulcer disease or GI bleeding
• Heart failure
• Concurrent anticoagulation therapy

Choose Colchicine (1.2 mg immediately, then 0.6 mg one hour later) if: 1, 2, 4

• Patient presents within 12 hours of symptom onset
• No severe renal impairment (GFR >30 mL/min)
• Not taking strong CYP3A4 or P-glycoprotein inhibitors (clarithromycin, cyclosporine, ritonavir)

Choose NSAIDs (full FDA-approved anti-inflammatory doses) if: 1, 3

• No renal impairment, cardiovascular disease, or GI contraindications
• Patient preference for this route
• Note: Indomethacin has no proven superiority over other NSAIDs like naproxen or ibuprofen 1

For monoarticular or oligoarticular gout (1-2 large joints), strongly consider intra-articular corticosteroid injection as it provides targeted therapy with minimal systemic exposure. 1, 2, 3

Severe or Polyarticular Attacks

For severe gout involving multiple joints, use combination therapy from the start: 1, 2

• Oral corticosteroids + colchicine, OR
• Intra-articular steroids + any oral anti-inflammatory agent, OR
• Colchicine + NSAIDs

This approach is more effective than monotherapy for severe presentations. 2

Specific Dosing Regimens

Prednisone/Prednisolone: 2

• Fixed-dose: 30-35 mg daily for 5 days (no taper needed for most patients)
• Weight-based: 0.5 mg/kg/day for 5-10 days at full dose, then stop OR 0.5 mg/kg/day for 2-5 days then taper over 7-10 days for severe attacks

Colchicine: 1, 2, 4

• Maximum 1.8 mg over one hour (1.2 mg immediately, 0.6 mg one hour later)
• Low-dose colchicine is strongly preferred over high-dose due to equal efficacy with significantly fewer GI adverse effects

NSAIDs: 1

• Use full FDA-approved anti-inflammatory doses
• Any potent NSAID is acceptable; no evidence supports indomethacin superiority

Critical Management Principle

Continue established urate-lowering therapy without interruption during an acute flare. 1, 2, 3 Stopping ULT worsens the flare and complicates long-term management. If the patient is not yet on ULT, you can conditionally start it during the flare with appropriate anti-inflammatory coverage. 2, 3

---

Urate-Lowering Therapy (ULT) Management

When to Initiate ULT

Do NOT initiate long-term ULT after a first gout attack or in patients with infrequent attacks (<2 per year). 1

Initiate ULT in patients with: 1

• Recurrent acute attacks (≥2 episodes per year)
• Arthropathy or tophi
• Radiographic changes of gout
• Chronic kidney disease with gout
• Urolithiasis

Shared Decision-Making Discussion

Before starting ULT, discuss with the patient: 1

• Benefits: Prevention of future attacks, crystal dissolution, prevention of joint damage
• Harms: Initial increase in flare frequency, medication side effects (rash with allopurinol, GI symptoms with febuxostat)
• Costs: Febuxostat is more expensive than allopurinol
• Duration: Likely lifelong therapy
• Alternative: Treat flares as they occur if infrequent

ULT Initiation and Titration

Start allopurinol at 100 mg daily and increase by 100 mg every 2-4 weeks until serum uric acid <6 mg/dL (ideally <360 μmol/L). 1, 5 The maximum dose is 800 mg daily. 5

Adjust allopurinol dose in renal impairment: 5

• CrCl 10-20 mL/min: 200 mg daily maximum
• CrCl <10 mL/min: 100 mg daily maximum
• CrCl <3 mL/min: Extend dosing interval beyond daily

Febuxostat 40 mg daily is equally effective as allopurinol 300 mg daily for lowering serum urate. 1

Therapeutic Target

The goal is to maintain serum uric acid below the saturation point for monosodium urate (<360 μmol/L or <6 mg/dL) to promote crystal dissolution and prevent crystal formation. 1

---

Mandatory Prophylaxis During ULT Initiation

All patients starting ULT must receive concomitant anti-inflammatory prophylaxis for 3-6 months to prevent treatment-induced flares caused by urate crystal mobilization. 1, 2, 3

Prophylaxis Options (in order of preference)

First-line: Low-dose colchicine 0.5-0.6 mg once or twice daily 1, 3

• Adjust dose in moderate renal impairment (halve the dose)
• Avoid in severe renal impairment (GFR <30 mL/min)
• Contraindicated with strong CYP3A4/P-gp inhibitors

Second-line: Low-dose NSAIDs (e.g., naproxen 250 mg twice daily) 1

• Use with gastric protection if indicated
• Avoid in renal impairment, cardiovascular disease, or GI contraindications

Third-line: Low-dose prednisone (<10 mg/day) 2, 3

• Use only if colchicine and NSAIDs are contraindicated, not tolerated, or ineffective
• Monitor for hyperglycemia, mood changes, and fluid retention

Duration of Prophylaxis

Continue prophylaxis for at least 3-6 months after ULT initiation, and longer if: 1, 2

• Clinical evidence of continuing gout disease activity persists
• Serum urate target has not yet been achieved
• Patient continues to experience flares

---

Critical Pitfalls to Avoid

Never delay acute treatment initiation—this is the most important determinant of success, not which agent you choose. 2, 3, 6

Never use colchicine in severe renal impairment (GFR <30 mL/min) or with strong CYP3A4/P-gp inhibitors (clarithromycin, cyclosporine, ritonavir)—fatal toxicity can occur. 2, 3, 4

Never stop established ULT during an acute flare—this worsens the attack and complicates long-term management. 1, 2, 3

Never start ULT without concomitant anti-inflammatory prophylaxis—this will trigger treatment-induced flares and poor adherence. 1, 2, 3

Never prescribe NSAIDs to patients with renal impairment, heart failure, or active peptic ulcer disease—corticosteroids are safer in these populations. 1, 2, 3

Never use high-dose colchicine (hourly dosing)—low-dose regimens are equally effective with significantly fewer adverse effects. 1, 2, 3

---

Special Populations

Severe CKD (GFR <30 mL/min): Oral corticosteroids are the safest first-line option; avoid colchicine and NSAIDs entirely. 2, 3

Patients unable to take oral medications: Use parenteral glucocorticoids (IM, IV, or intra-articular) over IL-1 inhibitors or ACTH due to safety and cost advantages. 2, 3

Patients with contraindications to all first-line agents: Consider IL-1 inhibitors (canakinumab 150 mg subcutaneously) only for frequent flares, but avoid if active infection is present. 2, 3